Mizuho has initiated coverage on Spyre Therapeutics Inc (SYRE) with an Outperform rating, marking its first assessment of the biotechnology firm. This rating reflects Mizuho's analysis of Spyre's investment potential, considering its innovative approach in developing next-generation human enzyme therapeutics aimed at treating rare and high-burden diseases.
Headquartered in Waltham, Massachusetts, Spyre Therapeutics is a clinical-stage company with a market capitalization of $2.1 billion. The firm currently employs 87 full-time staff and has a pipeline that includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Notably, its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody being developed for the treatment of inflammatory bowel disease (IBD).
The company's financial performance has shown variability, with an EPS (TTM) of -4.43. Recent earnings reports indicate a mixed trajectory, including a surprise of 80.3% in Q3 2025, where EPS was -0.15 against an estimate of -0.76. Looking ahead, upcoming earnings are projected for August 3, 2026, with an EPS estimate of -0.61.
Analyst ratings are based on extensive research and financial models, providing insights into potential investment opportunities. However, these assessments are subject to change as new information emerges. Investors are encouraged to consider a range of factors, including company fundamentals and industry trends, when evaluating investment decisions.
As of December 1, 2025, the analyst consensus for Spyre Therapeutics includes 10 Strong Buy ratings, 8 Buy ratings, and 1 Hold rating, reflecting a generally positive outlook from analysts in the field.